-

02:31:58 PM

RYTM Stock News

RYTM - Rhythm Pharmaceuticals Inc.

09/22/23 8:00 AM

Nasdaq : RYTM

high short

Rhythm Pharmaceuticals Presents New Data at ESPE 2023

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway

RHEA-AI

neutral

09/19/23 8:01 AM

Nasdaq : RYTM

acquisitionclinical trialhigh short

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway

RHEA-AI

neutral

09/08/23 4:01 PM

Nasdaq : RYTM

high short

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway

RHEA-AI

neutral

09/08/23 7:59 AM

Nasdaq : RYTM

high short

Rhythm Pharmaceuticals Announces Update to September Conference Participation

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway

RHEA-AI

negative

09/06/23 7:59 AM

Nasdaq : RYTM

high short

Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming

RHEA-AI

neutral

08/28/23 8:00 AM

Nasdaq : RYTM

conferenceshigh short

Rhythm Pharmaceuticals to Present at Investor Conferences in September

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway

RHEA-AI

negative

08/07/23 8:00 AM

Nasdaq : RYTM

high short

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

Rhythm Pharmaceuticals,

RHEA-AI

neutral

08/04/23 4:01 PM

Nasdaq : RYTM

high short

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway

RHEA-AI

neutral

08/01/23 7:00 AM

Nasdaq : RYTM

earningshigh short

Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update

Achieved commercial sales

RHEA-AI

neutral

07/19/23 8:00 AM

Nasdaq : RYTM

high short

Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families

RHEA-AI

negative

1 2 3 4 5 6 7 8 9 10 Next